Employing Steered MD Simulations for Effective Virtual Screening: Active Pharmacophore Search by Dynamic Corrections to target MKK3-MYC Interactions
Muhammet Eren Ulug, Saima IkramiD, Ehsan SayyahiD, Serdar DurdağıiD
Abstract
The intricate relationship between mitogen-activated protein kinase 3 (MKK3) and MYC proto-oncogene protein (MYC) activation holds deep implications for the progression of cancer, particularly in the context of triple negative breast cancer (TNBC). Despite significant progress, the challenge of discovering effective MYC-targeted drugs persists, demanding innovative approaches to control MYC-dependent malignancies. A promising avenue in this pursuit involves disrupting the protein-protein interactions (PPIs) between MKK3 and MYC. The significance of this interaction is emphasized by the activation of MYC by MKK3 in diverse cell types, presenting a novel perspective for therapeutic interventions in MYC-driven pathways. In the current study, a novel in silico strategy to screen small molecule libraries that target the MKK3-MYC interaction was conducted. Dynamic structure-based pharmacophore models were developed and utilized for screening the small molecule libraries, enabling the identification of compounds exhibiting favorable alignment with the defined pharmacophore features. Subsequently, physics-based simulations approaches were conducted on these selected hit molecules. Steered molecular dynamics (sMD) simulations were utilized to assess the correlation between the necessary forces to dissociate candidate hit ligands from the binding pocket and their corresponding average binding free energies (MM/GBSA). Comparative analysis of the average binding free energies of the identified hits obtained from the small molecule libraries represent that the identified compounds have promising predicted binding affinities compared to the reference molecule SGI-1027. Therefore, these findings may signify a crucial advancement in our ability to control MYC activation in cancer.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 3
- FWCI
- 1.54
- Field percentile
- top 19%
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Phytochemicals from Daucus carota have therapeutic potential against Triple-Negative Breast Cancer PDK1 and PLK1.
Kayode Yomi Raheem, Modinat Aina Abayomi, … Muhammad Muddassar·bioRxiv·Nov 4, 2024
- MYC Overexpression Confers Sensitivity to TACC3 Inhibition for Triple-Negative Breast Cancer
Mauricio Jacobo Jacobo, July Aung, … Andrei Goga·bioRxiv·Apr 29, 2026
- Development of a Bipyrimidineamide based α-Helix Mimetic Lead Compound for efficient Targeting of MDM2 in Triple-Negative Breast Cancer
Jasmin Linh On, Vitalij Woloschin, … Knud Esser·bioRxiv·Mar 2, 2024
- Characterising the Protein-Protein Interaction Between MDM2 and 14-3-3σ; Proof of Concept for Small Molecule Stabilisation
J. A. Ward, B. Romartinez-Alonso, … R. G. Doveston·bioRxiv·Sep 26, 2023
- Conformational drugging pockets at the surface of c-MYC proto-oncongenes
Yanhong Ge, Huixia Lu, Jordi Marti·bioRxiv·May 29, 2026
- From Virtual Screens to Cellular Target Engagement: New Small Molecule Ligands for the Immune Checkpoint LAG-3
Natalie S. Fuchs, Laura Calvo‐Barreiro, … Moustafa Tarek Gabr·ACS Medicinal Chemistry LettersPeer-reviewed·Oct 15, 2024